Vaginal Colonization With GBS
Conditions
Keywords
Streptococcus agalactiae, Group B Streptococcus, Neonates, colonization, meningitis, Clonal Complex CC17, microbiota, next generation sequencing (NGS)
Brief summary
Streptococcus agalactiae (GBS) is the leading cause of neonatal septicaemia, meningitis, and pneumonia in the industrialized world. Early onset (EOD) and late onset (LOD) diseases are defined in neonates by their occurring within or after the first week of life, respectively. Molecular epidemiological studies have identified a capsular serotype III clone, referred to as CC-17 by Multi Locus Sequence Typing, as accounting for the vast majority of neonatal invasive diseases and for almost all cases of meningitis in LOD. The investigators working hypothesis is that host-environmental interactions may contribute to the colonization and persistence of the hypervirulent CC-17 GBS in the neonate. In this project the investigators will determine if reciprocal interactions between the intestinal microbiota and the innate and adaptive immune system may specifically facilitate the colonization of the neonate by the hypervirulent GBS CC-17 clone.
Detailed description
Four specific tasks will be addressed to: (i) Understand whether and how the gut microbiota may influence growth and colonization of GBS CC-17 within the intestine of neonates. (ii) Study the contribution of different diets and immune system constituents enabling the persistence of GBS CC-17 in the gut of neonates. (iii) Determine whether the adaptive immune response elicited by maternal GBS colonization and transmitted to the infant is different for GBS CC-17 versus non-CC-17 GBS. (iv) Determine whether or not GBS strains isolated from the mothers and from their babies are identical and whether the environment (ie. the vagina or the milk for the mother, the intestine or the oral cavity for the baby) influence the expression of specific virulence factors of CC-17.
Interventions
BIOLOGICALBacteriological analyses on clinical samples performed with Eswabs
Clinical samples analysed : mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR
Sponsors
URC-CIC Paris Descartes Necker Cochin
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient having a negative vaginal swab for GBS at 35-37 weeks * Patient aged over 18 years * Patient who received information and agreeing to sign informed consent * Patient affiliated or beneficiary of an insurance
Exclusion criteria
* Patient does not speak and does not understand French
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Negative GBS screening in vaginal samples | 2 months |
Secondary
| Measure | Time frame |
|---|---|
| Number of Negative GBS screening in fecal samples . | 2 months |
| Number of Negative GBS screening in vaginal samples | At delivery |
Countries
France
Outcome results
None listed